HEMGENIX ®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases "CSL is humbled and honored to receive a Prix Galien award for ...
Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the ...
CSL, the leading European provider of critical IoT connectivity, is pleased to announce its strategic acquisition of EdgeConnect, a multi-award-winning specialist internet connectivity solutions ...
Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Hemophilia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
Hosted on MSN
Buffett backs CSL, Life360, WiseTech in latest move
CSL Limited is one of the world’s leading companies specializing in blood plasma therapies, nephrology, and vaccines. The company has an impressive track record of growth, driven by its commitment to ...
Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
It’s often said that knowledge is power, and that’s never been more true for businesses than in today’s digital age. Technology tools enable businesses to collect a wealth of information from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback